Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients

Maria Papp, Istvan Altorjay, Gary L. Norman, Zakera Shums, Karoly Palatka, Zsuzsanna Vitalis, Ildiko Foldi, Gabriella Lakos, Judit Tumpek, Miklos L. Udvardy, Jolan Harsfalvi, Simon Fischer, Laszlo Lakatos, Agota Kovacs, Laszlo Bene, Tamas Molnar, Zsolt Tulassay, Pal Miheller, Gabor Veres, Janos PappPeter Laszlo Lakatos, Peter Fuszek, Henrik Csaba Horvath, Peter Vargha, Ferenc Szalay, Zsuzsanna Erdelyi, Gabor Mester, Csaba Molnar, Tunde Pandur, Ferenc Nagy, Janos Lonovics, Demeter, Levente Balint, Pal Demeter, Ferenc Huoranszky, Istvan Dobo, Laszlo Herszenyi, Annamaria Nemeth

Research output: Contribution to journalArticle

67 Citations (Scopus)


Background: Antibodies directed against Saccharomyces cerevisiae (ASCA), perinuclear components of neutrophils (pANCA), and porin protein C of Escherichia coli (anti-OmpC) are reported to be associated with disease phenotype and may be of diagnostic importance in inflammatory bowel disease (IBD). Since limited data are available from Eastern Europe, we assessed the above antibodies in Hungarian IBD patients. Methods: In all, 653 well-characterized, unrelated consecutive IBD patients (Crohn's disease [CD]: 558, m/f: 263/295, duration: 8.1 ± 10.7 years; ulcerative colitis [UC]: 95, m/f: 44/51, duration: 8.9 ± 9.8 years) and 100 healthy subjects were investigated. Sera were assayed for anti-Omp and ASCA by enzyme-linked immunosorbent assay (ELISA) and ANCA by indirect immunofluorescence assay (IIP). TLR4 and NOD2/CARD15 variants were tested by polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP). Detailed clinical phenotypes were determined by reviewing the medical charts. Results: Anti-Omp, ASCA, and atypical pANCA antibodies were present in 31.2%, 59.3%, and 13.8% of CD, 24.2%, 13.7%, and 48.5% of UC patients, and in 20%, 16%, and 5.6% of controls, respectively. ASCA and anti-Omp positivity were associated with increased risk for CD (odds ratio [OR]ASCA = 7.65, 95% confidence interval [CI]: 4.37-13.4; OROmp = 1.81, 95% CI: 1.08-3.05). In a logistic regression analysis, anti-Omp and ASCA were independently associated with ileal and noninflammatory disease, but not with a risk for surgery or response to steroids or infliximab. A serology dosage effect was also observed. ASCA and anti-Omp antibodies were associated with NOD2/CARD15, in addition to a gene dosage effect. No associations were found in UC. Conclusions: Serological markers were useful in the differentiation between CD and UC in an Eastern European IBD cohort. Reactivity to microbial components was associated with disease phenotype and NOD2/CARD15 genotype, further supporting the role of altered microbial sensing in the pathogenesis of CD.

Original languageEnglish
Pages (from-to)984-992
Number of pages9
JournalInflammatory bowel diseases
Issue number8
Publication statusPublished - Aug 1 2007



  • ASCA
  • Atypical pANCA
  • Disease phenotype
  • IBD
  • NOD2/CARD15
  • Omp
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this